Global Breast Cancer Liquid Biopsy Market to Reach US$ 497.2 Million by 2032, Propelled by the Rising Prevalence of Breast Cancer

December 08, 2022 | Healthcare

The latest report by IMARC, titled “Breast Cancer Liquid Biopsy Market Report by Product Services (Reagent Kits, Instruments, Services), Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell-Free DNA (cfDNA), Extracellular Vesicles (EVs), and Others), End User (Reference Laboratories, Hospitals and Physician Laboratories, and Others), and Region 2024-2032”, finds that the global breast cancer liquid biopsy market size reached US$ 130.4 Million in 2023. Breast cancer liquid biopsy refers to a non-invasive medical process that uses blood as a sample for the recognition of tumor markers. It helps in evaluating the progression of breast cancer disease and detects Epidermal Growth Factor Receptor (EGFR) gene mutations that assist health professionals in choosing the best course of treatment at the appropriate time. Some of the most commonly used biomarkers include extracellular vesicles, circulating tumor cells (CTC), circulating tumor DNA, and others. In recent years, breast cancer liquid biopsy has gained traction as it offers numerous advantages, such as the characterization of new lesions, minimal invasiveness, drug and therapeutic target identifications for cancer treatment.

Global Breast Cancer Liquid Biopsy Market Trends:

One of the primary factors driving the market is the increasing number of individuals diagnosed with breast cancer. Additionally, breast cancer liquid biopsy offers multiple benefits, such as quicker results, minimal health risk, lower cost, non-invasiveness, and others, thereby creating a positive market outlook. Other than this, the surging demand for pre-screening programs for breast cancer detection, along with easy accessibility and extensive utilization of polymerase chain reaction (PCR) and next-generation sequencing (NGS) among clinical, is positively influencing the market growth. Besides this, numerous global organizations are conducting awareness campaigns in order to educate individuals about breast health and cancer diagnostic measures. In line with this, governments of numerous nations are offering reimbursement policies for breast cancer biopsy and other related medical procedures, consequently propelling market growth. Furthermore, key players are extensively investing in the introduction of advanced biopsy techniques that improve several aspects of breast cancer management, including early diagnosis of relapse, efficient longitudinal monitoring of diseases progress and response to treatment, and others. Looking forward, IMARC Group expects the market value to reach US$ 497.2 Million by 2032, expanding at a CAGR of 15.5% during the forecast period (2024-2032).

Market Summary:

  • Based on the product services, the market has been divided into reagent kits, instruments, and services.
  • On the basis of the circulating biomarker, the market has been segregated into circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vehicles (EVs), and others.
  • Based on the end user, the market has been segmented into reference laboratories, hospitals and physician laboratories, and others.
  • Region-wise, the market has been classified into North America (the United States and Canada), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa.
  • The competitive landscape of the market has also been analyzed, with some of the key players being Biocept Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, Fluxion Biosciences Inc., Guardant Health Inc., Illumina Inc., Menarini Silicon Biosystems (The Menarini Group), NeoGenomics Laboratories Inc., Qiagen, and Sysmex Europe SE (Sysmex Corporation).
     

Report Scope:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Million
Segment Coverage Product Services, Circulating Biomarker, End User, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Biocept Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, Fluxion Biosciences Inc., Guardant Health Inc., Illumina Inc., Menarini Silicon Biosystems (The Menarini Group), NeoGenomics Laboratories Inc., Qiagen and Sysmex Europe SE (Sysmex Corporation)
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
30 N Gould St, Ste 
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global Breast Cancer Liquid Biopsy Market to Reach US$ 497.2 Million by 2032, Propelled by the Rising Prevalence of Breast Cancer
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More